Arielle Medford

About Arielle Medford

Arielle Medford is a fourth-year medical student who spent this past year doing cancer research. She is also a dancer and a writer, and she loves everything science.

Posts by Arielle Medford:

Once-Daily Combination Pills Offer More Than Convenience

In November 2015, the FDA approved the HIV-1 medication Genvoya, a once-daily pill containing fixed doses of the HIV drugs elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide. This is the latest once-daily medication to be produced to treat HIV, a disease that used to be managed primarily with many different pills taken multiple times a day.(...)


Student Advocates for Sexual and Gender Minorities Healthcare in Curriculum

This past year, fourth-year medical student Ryan Shields undertook a big project. He sought to build on previous students’ efforts to improve medical education surrounding sexual and gender minorities (SGM), the broader category into which fit lesbian, gay, bisexual and transgender (LGBT) topics. After only a year and half, Ryan and his collaborators have already(...)


Fighting Obesity: A National Health Issue

It is no secret that weight loss is a major driver in American culture. In 2013, the U.S. weight loss market recorded a total market value of $60.5 billion1. And while there is certainly an aesthetic push behind weight loss culture, achieving a healthy weight is also incredibly important in terms of personal health. Almost(...)


End-of-Life Discussion: An Integral Component of Patient Care

Next year, Medicare plans to begin reimbursing doctors for end-of-life discussions. This development highlights the vital role doctors play in these discussions and the importance of determining patients’ wishes before illness prevents them from speaking for themselves.  This change in billing is important not because of the money itself, but because it puts end-of-life discussions(...)


Clinical Trial Shines Light on Sleep Disorders in Blind Patients

Last month, The Lancet published an article describing a recent phase III clinical trial in totally blind patients. The study evaluated the efficacy of a new medical intervention called tasimelteon for non-24-hour sleep-wake disorders.1 The science behind these conditions is simple. Circadian rhythm sleep-wake disorders result from discordance between an individual’s environment and the sleep-wake(...)


Legislative Bill Prompts Discussion of Cross-Talk in the Scientific Community

Earlier this month, the U.S. House of Representatives approved a bill directly impacting the biomedical research community. If approved by the Senate, the 21st Century Cures Act promises to increase the budget of the National Institutes of Health (NIH) and provide it with an additional $8.75 billion over the next five years. The Food and(...)